Canada’s Valeant Pharmaceuticals International (TSX: VRX), never shy to go for hostile takeover moves, says it has submitted a merger proposal to the board of directors of US Botox maker Allergan (NYSE: AGN), valuing the latter at around $45.6 billion.
Allergan's shares leapt 21% to $171.50 in after-hours trading, while Valeant gained over 10% to $139.05.
Under the proposed offer, each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. Shareholders will be able to elect a mix of cash and shares, subject to proration. The proposal represents a substantial premium based on Allergan's unaffected price of $116.63 on April 10, 2014 , the day before hedge fund Pershing Square Capital Management crossed the 5% Schedule 13D ownership level and commenced its rapid accumulation program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze